Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
29 March 2019 | Story Lacea Loader

No deregistration of students at the University of the Free State (UFS) will be effected until after the Financial Appeals Committee has concluded its process on 5 April 2019.

During a meeting between the university management and the Institutional Student Representative Council (ISRC) today, the following agreement was reached:

  1. The date for the submission of appeals has been extended to Tuesday 2 April 2019 at 12:00. No further extension will be given. The application form for the Financial Appeals Committee has previously been sent to the ufs4life email addresses of all provisionally registered students.
  2. Students who have appealed their National Student Financial Aid Scheme (NSFAS) outcomes will not be deregistered while awaiting the result of the outcome of their appeal.
  3. Verified final-year students who are provisionally registered will not be deregistered. This will be subject to verification by the Financial Appeals Committee. These students must also submit an appeal.
  4. All other categories of students must submit their appeals to the Financial Appeals Committee.

NB: The documentation mentioned above must be submitted to the Student Finance Office as indicated on the financial appeals form sent to students via their ufs4life email address.

The UFS has taken a pro-poor approach to assist students who are academically deserving. With this approach, the university’s fee structure is much less than that of many public institutions of higher learning in the country. Senior students are also supported through a provisional registration process that grants them the opportunity to pay a reduced amount in order to register, enabling them to fully participate in all activities while extension is provided to secure the necessary funding for their studies.

The university has made a number of concessions to ensure that students are not financially excluded during the 2019 academic year. Many of these concessions were raised by the ISRC on behalf of students and was agreed upon by the university management.  

These concessions include:

  1. Students who have confirmed NSFAS funding for 2019 with historic debt, are to secure registration. This has taken place before the announcement on 24 March 2019 by the Minister of Higher Education and Training, Naledi Pandor, that the historic debt of NSFAS students will be settled by the department.

     

  2. Students in the missing middle who received a gap grant in 2018, have been assisted to pay a lesser amount to register fully for 2019.

     

  3. Students with historic debt who are not receiving the gap grant have also been assisted to register for 2019. Acceptable payment plans for these students have been agreed upon with the university’s Student Finance Office.

     

  4. First-time entering students were assisted with a reduced first payment to enable them to register for 2019.

     

  5. Final-year students with historic debt of less than R20 000 who could not have been assisted in any of the above concessions explained above were allowed to register.

     

  6. Students who are provisionally registered and who could not find the necessary financial means, had the opportunity to submit appeals to the Financial Appeals Committee by 29 March 2019 to secure their registration. This committee comprises representatives of the university management, as well as members of the ISRC. This committee is scheduled to meet on 5 April 2019.

The above is evidence of the multi-layered efforts by the university to support academic deserving students as far as it is practically possible in order to avoid financial exclusion. Additionally, the university’s Student Finance Office has since the beginning of the academic year communicated extensively on the process with students who are at risk of being deregistered.  

Historically, less than 0,5% of registered students at the UFS are not able to find the necessary means to secure their registration.

To support students in their academic efforts, all matters pertaining to registration should be concluded by the end of the first term. A cut-off date is set by which all registration processes – including concessions – are to be concluded. This date – 31 March 2019 – has already been set in 2018, which is the result of consultation with all relevant stakeholders, including the IRSC.

This cut-off date has now been extended to Tuesday 2 April 2019 at 12:00.

Released by:

Lacea Loader (Director: Communication and Marketing)
Telephone: +27 51 401 2584 | +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za
Fax: +27 51 444 6393



News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept